Defining mechanisms of blood-brain barrier dysfunction in cerebral small vessel disease using advanced 3D in vitro models.
Defining mechanisms of blood-brain barrier dysfunction in cerebral small vessel disease using advanced 3D in vitro models.
批准号:
MR/W027119/1
负责人:
Mootaz Salman
金额:
$194.4万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
神经退行性疾病(ndd)是一种无法治愈的、使人衰弱的疾病,它会导致脑细胞的进行性死亡。这会导致运动障碍、认知能力下降和残疾增加。目前ndd的治疗方法治疗的是症状,而不是潜在的病理变化。因此,ndd是医疗保健提供者和研究科学家面临的主要挑战。ndd主要发生在老年人中,他们是脑血管疾病(cSVD)的常见病,在全球范围内造成了至少45%(约2100万人)的痴呆。痴呆症的社会总成本为每年260亿英镑,其中包括86亿英镑的国民保健制度和社会护理费用。在了解分子病理的基础上开发新的治疗方法,这是一个明确的、尚未满足的临床需求。人类大脑需要一个稳定的微环境来确保正常运作。一种专门的多细胞血管结构,血脑屏障(BBB),调节血液和大脑之间的分子流动。NDD发展的一个关键方面是血脑屏障的渗漏和炎症介质(作用于血管和/或细胞以促进炎症反应的信使)在大脑周围的扩散。我们不清楚这些介质是如何穿过紧密屏障并导致血脑屏障分解的,也不清楚不同的血脑屏障细胞在这些过程中的确切作用。ndd的病理生理机制多样,迫切需要有效的治疗。许多先前被证明对动物有效的药物在人类身上没有产生同样的效果,仅仅是因为我们不同。此外,动物研究不允许在没有继发性、年龄相关并发症的模型中研究疾病机制,而基于2D细胞的模型往往过于简化,无法充分概括血脑屏障生物学。出于这个原因,我设计了一个更简单、更快、更与生理相关的人类细胞疾病模型。在这个项目中,我将开发我的新颖的、动态的、微生理的“芯片上的bbb”,它模仿人类大脑的相关生理和功能。我将确定血压、血流量和心跳等因素如何控制血脑屏障的功能。我将使用直接从人类大脑中获取的细胞(原代细胞)和具有csvd相关基因突变的干细胞,使用最先进的基因编辑工具CRISPR-Cas9来生成与生理相关的人类疾病模型。我将研究在完整的血脑屏障或泄漏的血脑屏障支持下,脑细胞的生物学变化。在生理模型中对血脑屏障功能的新分析将导致与cSVD进展相关的新细胞过程的鉴定,并帮助我们了解如何利用血脑屏障来保护大脑免受疾病的侵害。使用任何其他方法都不可能做到这一点。因此,我准备对健康和疾病中的大脑功能进行重大的新认识,并发现新的药物和靶点,可以阻止相关痴呆症的发生和发展。
英文摘要
Neurodegenerative disorders (NDDs) are incurable and debilitating conditions that result in the progressive death of brain cells. This leads to movement disorder, cognitive decline and increased disability. Current therapies for NDDs treat symptoms, not the underlying pathological changes. The NDDs are therefore major challenges to healthcare providers and research scientists. NDDs occurs mostly in older people in whom cerebral small vessel disease (cSVD) is common and contributes to at least 45% (~21 million people) of dementia worldwide. The aggregate societal cost of dementia is £26 billion per year, including £8.6 billion for NHS and social care. There is a clear and unmet clinical need to develop new therapies based on understanding the molecular pathologies.The human brain needs a stable microenvironment to ensure proper functioning. A specialized multi-cellular blood vessel structure, the blood-brain barrier (BBB), regulates the flow of molecules between the blood and the brain. A key aspect of NDD development is the leakiness of the BBB and the spread of inflammatory mediators (messengers that acts on blood vessels and/or cells to promote an inflammatory response) around the brain. We do not understand how these mediators cross the tight barrier and cause BBB breakdown, or the precise role of different BBB cells in these processes.NDDs are diverse in their pathophysiology and effective treatments are urgently needed. Many drugs that have been previously shown to be effective in animals have failed to produce the same effects in humans, simply because we are different. Moreover, animal studies do not allow studying disease mechanisms in a model that is free from secondary, age-related complications, while 2D cell-based models are often too simplified to sufficiently recapitulate BBB biology. For this reason, I have designed a simpler, faster, and more physiologically-relevant human cellular model of disease. In this project, I will develop my novel, dynamic, microphysiological 'BBB-on-a-chip' that mimics the relevant physiology and functionality of the human brain. I will determine how factors such as blood pressure, blood flow rate and heartbeat control BBB function. I will use cells harvested directly from human brains (primary cells) and stem cells with cSVD-relevant genetic mutations using a state-of-the-art genetic editing tool called CRISPR-Cas9 to generate a physiologically-relevant human disease model. I will investigate how the biology of brain cells changes when supported by an intact or a leaky BBB. This new analysis of BBB function in a physiological model will lead to the identification of new cellular processes relevant to cSVD progression, and help us understand how to harness the BBB to shield the brain from disease.This is not possible using any other approach. I am therefore poised to develop significant new understanding of brain function in health and disease and discover new drugs and targets that can stop the occurrence and development of related dementias.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/jnc.16029
发表时间:
2023-12-16
期刊:
JOURNAL OF NEUROCHEMISTRY
影响因子:
4.7
作者:
[Markou,Andrea, Kitchen,Philip, Balklava,Zita]
通讯作者:
Balklava,Zita
国内基金
海外基金
登录
查看更多内容
Exploring the Intrinsic Mechanisms of CEO Turnover and Market
-
批准号:--
-
项目类别:外国学者研究基金
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI Z
-
依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
-
批准号:W2433169
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI ZHANG
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
-
批准号:82370979
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张善勇
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
Idh3a作为线粒体代谢—表观遗传检查点调控产热脂肪功能的机制研究
-
批准号:82370851
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:包玉倩
-
依托单位:
小脑浦肯野细胞突触异常在特发性震颤中的作用机制及靶向干预研究
-
批准号:82371248
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:吴逸雯
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
用于小尺寸管道高分辨成像荧光聚合物点的构建、成像机制及应用研究
-
批准号:82372015
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:熊丽琴
-
依托单位: